|
The inspection was conducted by the US drug regulator from 5 June 2023 to 9 June 2023. At the end of the inspection, the facility received 'No Observations' and thus, No Form 483 was issued.
The company said that it remains committed to producing quality products, embedding a quality culture across the organization and continuously investing in systems, processes & training of its employees so that it can maintain the highest standards of quality and compliance for all its markets.
J. B. Chemicals & Pharmaceuticals is a pharmaceutical company manufacturing & marketing a diverse range of pharmaceutical formulations, herbal remedies and APIs.
The company's consolidated net profit rose 3.3% to Rs 87.63 crore on 22.1% increase in net sales to Rs 762.32 crore in Q4 FY23 over Q4 FY22.
The scrip declined 1.39% to currently trade at Rs 2,131.15 on the BSE.
|